Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress
Retrieved on:
Saturday, June 17, 2023
PK, Communication, LDHA, Half-life, Urine, EKG, Safety, LDH, SAD, CKD, Inflammation, Cell, ERA, Congress, Plasma, Fibrosis, SAE, Vital signs, HIV disease progression rates, Patient, Anaphylaxis, Primary hyperoxaluria, Kidney, Adrenaline, Blood, Nature, MAD, HV, Therapy, Headache, Phenotype, Biopsy, Vaccine, Pharmaceutical industry, Dietary supplement
The phase 1 single-center trial (see www.clinicaltrials.gov , identifier NCT05367661) was designed to evaluate the safety, tolerability, pharmacokinetic profile of CHK-336 in 104 healthy volunteers in randomized, placebo-controlled, double-blinded, single-ascending dose (SAD) and multiple-ascending dose (MAD) settings.
Key Points:
- The phase 1 single-center trial (see www.clinicaltrials.gov , identifier NCT05367661) was designed to evaluate the safety, tolerability, pharmacokinetic profile of CHK-336 in 104 healthy volunteers in randomized, placebo-controlled, double-blinded, single-ascending dose (SAD) and multiple-ascending dose (MAD) settings.
- Healthy volunteers in the SAD portion of the study received placebo or a single dose of CHK-336 ranging from 15 mg to 500 mg on day 1.
- The most common treatment emergent adverse event was headache in six subjects receiving CHK-336 (8.8%) and no placebo subjects, with no dose-related trend.
- The emergence of maladaptive tubules is associated with disease progression across multiple CKDs and targeting these cells may potentially be an effective strategy to preserve kidney function broadly in CKD.